Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial
Pharmacology, Toxicology and Pharmaceutical Science
5
5%
Other
9
9%
Unknown
48
49%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 160. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 September 2026.
All research outputs
#322,803
of 34,528,520 outputs
Outputs from Lancet Infectious Diseases
#618
of 7,205 outputs
Outputs of similar age
#7,207
of 458,244 outputs
Outputs of similar age from Lancet Infectious Diseases
#28
of 130 outputs
Altmetric has tracked 34,528,520 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 7,205 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 85.0. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 458,244 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 130 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.
